Cancer Gene Therapy Market Insightful Details and Healthcare Experts Review Report 2021-2030

The Global Cancer Gene Therapy Market size valued to USD 558.24 million in 2019, is predicted to reach USD 16.50 billion by 2030, with a CAGR of 32.6% from 2020-2030

Gene therapy is a technique to treat or prevent diseases, by using specific genes to replace the mutated gene causing disease or inactivate the mutated gene not functioning properly, or introducing an entirely new gene into the patient’s body to assist in fighting the disease.

Cancer gene therapy is gaining momentum due to high success rates achieved during pre-clinical and clinical trials. There are several experiments and researches going on to replace the use of conventional drugs and surgeries with gene therapy to treat cancer; as it causes least side effects and offers maximum efficacy.

Access Full Description of this report at:-

https://www.nextmsc.com/report/cancer-gene-therapy-market

Competitive Landscape :

Comprehensive competitive analysis and profiles of the major market players such as Bluebird bio, Inc., Merck, Adaptimmune, GlaxoSmithKline, Anchiano Therapeutics, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Celgene, Shanghai Sunway Biotech, OncoGenex Pharmaceuticals, and others are provided in the cancer gene therapy market report.

An upsurge in R&D activities and advancement in product technologies and new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global cancer gene therapy market.

For instance, in January 2020, Merck and AstraZeneca, one of the key players of cancer gene therapy market, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for their regulatory submission of supplemental New Drug Application of LYNPARZA (Olaparib) for the treatment of patients suffering from metastatic castration-resistant prostate cancer as well as deleterious, suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, that have progressed a prior treatment with a new hormonal agent. During the clinical trials, LYNPARA met its primary as well as secondary endpoints of radiographic progression-free survival in the overall population of men with HRR-mutated metastatic castration resistant. prostate cancer, by reducing the risk of disease progression or death by 66% and 51% respectively in both the trials.

Furthermore, at the American Society for Gene and Cell Therapy Annual meeting held in May 2020, Adaptimmune Therapeutics Plc., a leader in T-cell therapy to treat cancer and one of the major players of cancer gene therapy market, presented its advances from its Allogeneic Platform demonstrating that SPEAR T (Specific Peptide Enhanced Affinity Receptor) -T-cells engineered from Stem-Cells targeting MAGE-A4+ can kill tumor cells in vitro as effectively as control cells. Adaptimmune plans to build large banks of pluripotent cells for their proprietary differentiation process, to generate functional T-cells expressing Adaptimmune’s engineered receptors. This creates a milestone in building cell banks for clinical use in the cancer gene therapy market.

Request sample copy of this report at:-

https://www.nextmsc.com/Cancer-Gene-Therapy-Market/request-sample

Market Segmentations and Scope of the Study:

The cancer gene therapy market share has been analyzed based on therapy, end-user, and geography.

Based on therapy, the cancer gene therapy market is classified into gene induced immunotherapy, gene transfer, and oncolytic virotherapy. The gene induced immunotherapy is further sub-segmented into the delivery of cytokines gene and delivery of tumor antigen gene. The gene transfer is further sub-segmented into naked/plasmid vectors, sonoportion, magnetofection, electroporation, and gene gun. The oncolytic virotherapy segment is further sub-segmented into adenovirus, lentivirus, vaccinia virus, herpes simplex virus, alpha virus, retro virus, adeno associated virus, simian virus, and others. Based on application, the cancer gene therapy market is divided into hospitals, diagnostics centers, and research institutes. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America region dominated the global cancer gene therapy market in the past, and is expected to maintain its dominance throughout the forecast period, accounting for the highest market share. The growing number of geriatric populations, well-established health-care infrastructures with specialized medical practitioners, advanced technological developments at the product front, presence of major manufactures and key players as well as higher adoption of cancer gene therapy treatment in this region, are the factors expected to boost-up the cancer gene therapy market growth.

Asia Pacific region is expected to demonstrate a substantial growth in the cancer gene therapy market, with considerable CAGR values throughout the forecast period. Increasing consumer awareness about cancer gene therapy, increasing government initiatives in propagating this treatment, improvement in healthcare infrastructures as well as untapped market offered by emerging economies, are further expected to propel the growth of cancer gene therapy market.

Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.